Nkarta, Inc. (NASDAQ:NKTX) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC reduced its stake in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 14.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 757,075 shares of the company's stock after selling 127,197 shares during the quarter. Renaissance Technologies LLC owned approximately 1.07% of Nkarta worth $1,885,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in Nkarta by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company's stock valued at $5,294,000 after buying an additional 33,927 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Nkarta by 252.1% in the third quarter. JPMorgan Chase & Co. now owns 1,063,362 shares of the company's stock valued at $4,806,000 after purchasing an additional 761,349 shares during the period. Franklin Resources Inc. bought a new position in Nkarta in the third quarter worth approximately $151,000. Wellington Management Group LLP raised its position in Nkarta by 4.1% during the 4th quarter. Wellington Management Group LLP now owns 225,224 shares of the company's stock valued at $561,000 after purchasing an additional 8,883 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Nkarta by 1.4% in the 3rd quarter. State Street Corp now owns 1,098,062 shares of the company's stock worth $4,963,000 after buying an additional 15,569 shares during the period. 80.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Needham & Company LLC restated a "buy" rating and set a $11.00 price target on shares of Nkarta in a research note on Wednesday, April 9th. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Nkarta in a report on Thursday, March 27th. Finally, Stifel Nicolaus dropped their price objective on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 27th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Nkarta presently has a consensus rating of "Buy" and an average target price of $14.86.

Nkarta Stock Performance

NASDAQ:NKTX traded up $0.13 during midday trading on Wednesday, reaching $2.08. 256,880 shares of the stock traded hands, compared to its average volume of 1,089,477. The business has a 50-day moving average of $1.75 and a two-hundred day moving average of $2.37. Nkarta, Inc. has a 12-month low of $1.31 and a 12-month high of $8.33. The stock has a market capitalization of $147.59 million, a PE ratio of -1.11 and a beta of 0.83.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, March 26th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.06. Research analysts anticipate that Nkarta, Inc. will post -1.7 earnings per share for the current year.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.